Protection against Multiple Subtypes of Influenza Viruses by Virus-Like Particle Vaccines Based on a Hemagglutinin Conserved Epitope

Table 2

Antibody responses against LAH-HBc in mice induced by intranasal (i.n.) administration of LAH-HBc with or without .

Group	Immunogen	Immunization route	Dosage (μg)	Ab responses (ELISA, 2^n)
				Serum IgG	Nasal wash IgA
A	LAH-HBc + CTB^*	i.n.	25	14.67 ± 0.53	6.00 ± 0.43
B	LAH-HBc	i.n.	25	14.33 ± 0.83	3.36 ± 0.78
C	LAH-HBc + CTB^*	i.n.	5	11.3 ± 0.67	1.30 ± 0.88
D	LAH-HBc	i.n.	5	9.33 ± 0.81	Undetected
E	LAH-HBc + CTB^*	i.n.	1	8.00 ± 0.95	Undetected
F	LAH-HBc	i.n.	1	7.03 ± 0.43	Undetected
G	CTB^*	i.n.	—	Undetected	Undetected
H	Control	i.n.	—	—	—

Mice were immunized with LAH-HBc vaccine with or without CTB^* as described in Table 1. The serum samples and nasal washes were examined by ELISA for specific IgG and IgA Abs, respectively.
Results are expressed as means ± SD of tested mice in each group.